Orion Oyj (HEL:ORNAV)

Market Cap	9.76B
Revenue (ttm)	1.68B
Net Income (ttm)	378.00M
Shares Out	n/a
EPS (ttm)	2.69
PE Ratio	25.82
Forward PE	20.85
Dividend	1.64 (2.50%)
Ex-Dividend Date	Oct 15, 2025

Volume	31,028
Average Volume	9,348
Open	66.00
Previous Close	65.70
Day's Range	65.40 - 69.30
52-Week Range	39.35 - 69.30
Beta	0.37
RSI	74.87
Earnings Date	Jul 18, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,880
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNAV

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.